Current and future use of umifenovir in patients with COVID-19

At the time of print, the evidence for using umifenovir in COVID-19 is mainly theoretical. The published clinical trials have contradicting results. The decision to use umifenovir in COVID-19 should be individualized, considering the “experimental” nature of this treatment.

coronavirus, umifenovir, COVID-19

1. State register of medicines. ЛСР-003900/07. (In Russ). Доступно по: https://grls.rosminzdrav.ru/ Ссылка активна на 30.05.2020

2. Fink SL, Vojtech L, Wagoner J et al. The Antiviral Drug Arbidol Inhibits Zika Virus. Sci Rep. 2018 Jun 12;8(1):8989. DOI: 10.1038/s41598-018-27224-4

3. Hulseberg CE, Feneant L, Szymanska-de Wijs KM et al. Arbidol and Other Low-Molecular-Weight Drugs That Inhibit Lassa and Ebola Viruses. J Virol. 2019 Apr 3;93(8): e02185-18. DOI: 10.1128/JVI.02185-18

4. Li MK, Liu YY, Wei F et al. Antiviral activity of arbidol hydrochloride against herpes simplex virus I in vitro and in vivo. Int J Antimicrob Agents. 2018 Jan;51(1):98-106. DOI: 10.1016/j.ijantimicag.2017.09.001

5. Blaising J, Polyak SJ, Pecheur EI. Arbidol as a broad-spectrum antiviral: an update. Antiviral Res. 2014 Jul;107:84-94. DOI: 10.1016/j.antiviral.2014.04.006

6. Pecheur EI, Borisevich V, Halfmann P, et al. The Synthetic Antiviral Drug Arbidol Inhibits Globally Prevalent Pathogenic Viruses. J Virol. 2016 Jan 6;90(6):3086-92. DOI: 10.1128/JVI.02077-15

7. THE PROVISIONAL GUIDELINES. Prevention, diagnosis and treatment of new coronavirus infection (COVID-19) 7th ed., Moscow: Ministry of health of the Russian Federation, 2020 (In Russ). Доступно по: https://static-0.rosminzdrav.ru/system/attachments/attaches/000/050/584/original/03062020_%D0%9CR_COVID-19_v7.pdf Ссылка активна на 30.05.2020

8. Wright ZVF, Wu NC, Kadam RU, et al. Structure-based optimization and synthesis of antiviral drug Arbidol analogues with significantly improved affinity to influenza hemagglutinin. Bioorg Med Chem Lett. 2017;27(16):37443748. DOI: 10.1016/j.bmcl.2017.06.074

9. Wang X, Cao R, Zhang H, et al. The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro. Cell Discov. 2020 May 2;6:28. DOI: 10.1038/s41421-020-0169-8

10. Naveen V. Arbidol: A potential antiviral drug for the treatment of SARSCoV-2 by blocking trimerization of the spike glycoprotein. Int J Antimicrob Agents. 2020 Aug;56(2):105998. DOI: 10.1016/j.ijantimicag.2020.105998

11. Atanu Barik, Geeta Rai, Gyan Modi. Molecular docking and binding mode analysis of selected FDA approved drugs against COVID-19 selected key protein targets: An effort towards drug repurposing to identify the combination therapy to combat COVID-19. arXiv:2004.06447 [q-bio.BM] (or arXiv:2004.06447v1 [q-bio.BM] for this version)

12. Najim A. Al-Masoudi, Rita S. Elias, Bahjat Saeed. Molecular Docking Studies of some Antiviral and Antimalarial Drugs Via Bindings to 3CLProtease and Polymerase Enzymes of the Novel Coronavirus (SARSCoV-2). Biointerfaceresearch. 6444 2020;10(5):6444-6459. DOI: 10.33263/BRIAC105.64446459

13. Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia. [Internet]. [cited 2020 March 3]; Available from: https://www.elotus.org/promo-files/COVID-19_resources/Guidance%20for%20Corona%20Virus%20Disease%202019%20(English%207th%20Edition%20Draft).pdf

14. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. [Internet]. [cited 2020 March 3]; Available from: https://www.covid19treatmentguidelines.nih.gov/

15. Nicastri E, Petrosillo N, Bartoli TA.National Institute for the Infectious Diseases «L. Spallanzani», IRCCS. Recommendations for COVID-19 clinical management. Infect Dis Rep. 2020 Mar 16;12(1):8543. doi: 10.4081/idr.2020.8543

16. Clinical management of patients with COVID-19: Second interim guidance. [Internet]. [cited 2020 August 17]; Available from: https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirusinfection/clinical-management-covid-19.html

17. https://covid19evidence.net.au/

18. Clinical management of COVID-19. [Internet]. Available from: https://www.who.int/publications/i/item/clinical-management-of-covid-19WHO/2019-nCoV/clinical/2020.5

19. Zhu Z, Lu Z, Xu T et al. Arbidol monotherapy is superior to lopinavir/ ritonavir in treating COVID-19 [published online ahead of print, 2020 Apr 10]. J Infect. 2020 Jul;81(1):e21-e23. DOI: 10.1016/j.jinf.2020.03.060

20. Chen W, Yao M, Fang Z et al. A study on clinical effect of Arbidol combined with adjuvant therapy on COVID-19. J Med Virol. 2020 Jun 8;10.1002/jmv.26142. DOI: 10.1002/jmv.26142

21. Deng L, Li C, Zeng Q et al. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort. J Infect. 2020 Jul;81(1):e1-e5. DOI: 10.1016/j.jinf.2020.03.002

22. Lian N, Xie H, Lin S et al. Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study. Clin Microbiol Infect. 2020 Jul;26(7):917-921. DOI: 10.1016/j.cmi.2020.04.026

23. Liu Q, Fang X, Tian L et al. The effect of Arbidol Hydrochloride on reducing mortality of Covid-19 patients: a retrospective study of real world date from three hospitals in Wuhan. [Posted April 17, 2020]. Medrxiv. DOI: 10.1101/2020.04.11.20056523

24. Zhang JN, Wang WJ, Peng B, et al. Potential of Arbidol for Postexposure Prophylaxis of COVID-19 Transmission-A Preliminary Report of a Retrospective Cohort Study. Curr Med Sci. 2020 Jun;40(3):480-485. DOI: 10.1007/s11596-020-2203-3

25. Реестр разрешений на проведение клинических исследований https://grls.rosminzdrav.ru/CiPermitionReg.aspx

26. Clinical trials for covid-19 and umifenovir. EU Clinical Trials Register. Available from: https://www.clinicaltrialsregister.eu/ctr-search/search?query=covid-19+and+umifenovir

27. Liu X, Huang T, Chen JX et al. Arbidol exhibits strong inhibition towards UDP-glucuronosyltransferase (UGT) 1A9 and 2B7. Pharmazie. 2013 Dec;68(12):945-950.

28. Dmitriev A, Filimonov D, Lagunin A et al. (2019). Prediction of severity of drug-drug interactions caused by enzyme inhibition and activation. Molecules. 2019 Oct 31;24(21):3955. DOI: 10.3390/molecules24213955